REG - Genedrive PLC - Multi-partner grant awarded

GenedriveAnnouncement

16/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230616:nRSP8873Ca&default-theme=true

RNS Number : 8873C  Genedrive PLC  16 June 2023

genedrive plc

("genedrive" or the "Company")

 

Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit
in time critical NHS settings

 

Manchester NHS Industry partnership programme for rapid genomic test
implementation

genedrive plc (the "Company"), the point of care molecular diagnostics
company, today announces its participation in a multi-partner grant award
("DEVOTE") from Innovate UK and the UK government Innovation Accelerator
programme  with funding expected to be made available to further
 the validation and implementation of the new Genedrive® CYP2C19 ID Kit
pharmacogenetic test in a time critical clinical setting.

The Development and Validation of Technology for Time Critical Genomic Testing
(DEVOTE) grant will provide acute care patient access and supporting
infrastructure for the Company to assess the real world clinical performance
of time-critical clinical tests in an NHS settings. The programme, led by the
University of Manchester (UoM), builds on the model of the previous successful
UoM/genedrive partnership with the PALOH programme, which supported the
development and evaluation of the Genedrive® MT-RNR1 ID Kit which has
recently received a recommendation from NICE.

DEVOTE pulls together health economists, clinicians, informaticians, and
researchers to quickly access new technologies, and provide feedback in an
iterative fashion.  Genedrive's CYP2C19 ID Kit is one of three exemplar
projects to be included in the programme which is expected to be funded
through the Innovate grant, in-kind contributions, and other aligned funding.
In the main, funding is expected  to go directly to the UoM and its NHS
partners to set up and coordinate the three projects, the total amount of
funding to be made available under the programme will be determined in due
course.

DEVOTE will focus on ischaemic stroke patients in acute care who are targeted
to be prescribed Clopidogrel to prevent further clot formation. Clopidogrel is
less efficacious in individuals with certain genetic CYP2C19 variants because
they do not metabolize Clopidogrel effectively. Genedrive's CYP2C19 ID Kit is
being developed to provide guidance at the point of care on which patients
will respond fully to Clopidogrel. Patients with gene variants that result in
reduced or loss of function of CYP2C19 can be given alternative treatments.

Programme participants include genedrive, the University of Manchester (UoM),
Health Innovation Manchester and Manchester University NHS Foundation Trust
(MFT).  The DEVOTE programme will be led by Professor William Newman,
Professor of Translational Genomic Medicine at the University of Manchester
and Consultant at Saint Mary's Hospital, part of Manchester University NHS
Foundation Trust. Additional and ongoing project information is available at
https://www.devoteprogramme.co.uk/ (https://www.devoteprogramme.co.uk/)

Professor William Newman said: "We look forward to working with genedrive and
our other DEVOTE programme colleagues in Manchester to develop a framework for
time-critical pharmacogenetics, and to provide the framework for assessment of
implementation of the Genedrive® CYP2C19 ID Kit in emergency care. DEVOTE
will further establish the Manchester environ as a world recognised centre for
the development and implementation of pharmacogenomic testing."

 

David Budd, Chief Executive Officer of genedrive plc, said: "DEVOTE is an
amazing opportunity to engage formally with a health system like the NHS to
demonstrate the effectiveness of a new diagnostic approach. Access to the
Acute Medicine Unit in real time has considerable value to genedrive as
further funding would allow us to progress ongoing product development quickly
and efficiently, and would support the pathway to clinical validation of our
Genedrive® CYP2C19 ID Kit. This level of clinical input and evaluation is
increasingly required by regulatory authorities prior to marketing product
especially in the EU.  We are privileged to continue with our partners at UoM
and MFT in developing time-critical genetic test solutions."

 

For further details please contact:

 

 genedrive plc                                       +44 (0)161 989 0245
 David Budd: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel / Oliver Duckworth

 finnCap (Joint Broker)                              +44 (0)20 7220 0500
 Geoff Nash / Alice Lane

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )  genedrive plc is a molecular diagnostics
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need molecular diagnostics platform for the diagnosis
of infectious diseases and for use in patient stratification (genotyping),
pathogen detection and other indications. The Company has assays on the market
for the detection of MT-RNR1, HCV, certain military biological targets, a high
throughput SARS-CoV-2 assay and a point of care test for Covid-19. The company
are currently developing a genetic test for CYP2C19 metaboliser status.

 

About DEVOTE

The Development and Validation of Technology for Time Critical Genomic Testing
(DEVOTE) Programme is a collaboration between academics, clinicians, and
industry partners. It aims to accelerate the adoption of genomic technology
into clinical practice by supporting companies through each aspect of the
translational pathway.

 

For more information contact info@devoteprogramme.com
(mailto:info@devoteprogramme.com) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUVUORORUNAAR